JP MORGAN/PUT/VERTEX PHARMACEUTICALS/255/0.1/17.01.25

JP MORGAN/PUT/VERTEX PHARMACEUTICALS/255/0.1/17.01.25 Stock

DE000JL22HL9

Delayed Börse Stuttgart 05:13:20 2024-07-09 am EDT
0.072 ^EUR	-23.40%

Current month	-34.55%
1 month	+1.41%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart VERTEX PHARMACEUTICALS INCORPORATED

Chart JP MORGAN/PUT/VERTEX PHARMACEUTICALS/255/0.1/17.01.25

Latest news about VERTEX PHARMACEUTICALS INCORPORATED

Morgan Stanley Adjusts Price Target on Vertex Pharmaceuticals to $455 From $402	08:33am	MT
RBC Raises Price Target on Vertex Pharmaceuticals to $431 From $421, Keeps Sector Perform Rating	Jul. 09	MT
FDA move illuminates key role of telomere targeting as a viable therapeutic strategy for cancer treatment	Jul. 09	AQ
FDA Accepts Vertex Pharmaceuticals' New-Drug Application for Combination Therapy to Treat Cystic Fibrosis	Jul. 02	MT

More news

Quotes 5-day view

Date	Price	Change
24-07-09	0.072	-23.40%
24-07-08	0.094	-6.00%
24-07-05	0.1	-9.09%
24-07-04	0.11	+10.00%
24-07-03	0.1	-9.09%

Delayed Quote Börse Stuttgart

Last update July 09, 2024 at 05:13 am EDT

More quotes

Static data

Product type	Warrants
Buy / Sell	PUT
Underlying	VERTEX PHARMACEUTICALS INCORPORATED
Issuer	J.P. Morgan
WKN	JL22HL
ISIN	DE000JL22HL9
Date issued	2023-04-28
Strike	255 $
Maturity	2025-01-17 (190 Days)
Parity	10 : 1
Emission price	2.01 €
Emission volume	N/A
Settlement	règlement en espèces
Currency	EUR

Technical Indicators

Highest since issue	2.51 €
Lowest since issue	0.071 €
Delta	-0.02x
Omega	6.232
Premium	47.8x
Gearing	263.15x
Moneyness	0.5258
Difference Strike	-237.7 $
Difference Strike %	-93.22%
Spread	0.199 €
Spread %	73.70%
Theoretical value	0.1705
Implied Volatility	51.56 %
Total Loss Probability	94.62 %
Intrinsic value	0.000000
Present value	0.1705
Break even	253.16 €
Theta	-0.02x
Vega	0.02x
Rho	-0.01x

Company Profile

Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).

Sector

More about the company

Ratings for Vertex Pharmaceuticals Incorporated

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Consensus: Vertex Pharmaceuticals Incorporated

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

491.6 USD

Average target price

473.1 USD

Spread / Average Target

-3.77%

Consensus